Business
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April:
About this update from Immunic, Inc.
[{"type":"text","content":"NEW YORK, April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April:","length":336,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"April 5-9: American Academy of Neurology (AAN) 2025 Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in San Diego, California. The team will be available throughout the event at booth #2233.","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"April 9-10: German Biotech Days 2025 (Deutsche Biotechnologietage, DBT 2025). Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present "Vidofludimus Calcium – Designed to Combine the Best of Two Worlds: Neuroprotection and Relapse Prevention," highlighting lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), as well as Immunic's journey from company foundation to late-stage clinical trials, during a symposia at this conference in Heidelberg, Germany. The presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.","length":682,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Symposia: All Grown Up? Mature Biotech Companies Present their Progress","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Date: Wednesday, April 9, 2025","length":43,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Time: 2:20-3:30 pm CET (8:20-9:30 am ET)","length":53,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Location: Saal 2","length":29,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":201,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":1132,"olType":false},{"type":"text","content":"About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-...